Sumitomo Dainippon Pharma Co. Ltd. (SDP) has entered into a memorandum of understanding to acquire multiple Roivant Sciences GmbH assets, including ownership interests in up to 11 “vant” companies and other platform technologies, in a planned deal worth $3bn (around JPY320bn).
$3bn Roivant Deal To Fill Holes At Dainippon
Facing looming expiries for its top product, Japan’s Sumitomo Dainippon is planning to acquire multiple "vant" companies and their portfolios of clinical stage assets from Roivant, in a move to address mid-term challenges to revenues and following recent late-stage development failures.
